2014 Annual Meeting | 1HC.003 - Assessment of Rapidly Progressive Dementias and Related Neurologic Conditions

Date Saturday 04/26/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Steven Vernino, MD, PhD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be familiar with the differential diagnoses and work-up of common and uncommon conditions that may present as RPDs, including Creutzfeldt-Jakob disease (CJD), autoimmune and paraneoplastic encephalopathy, viral encephalitis, and their many imitators.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic

Event Timeline
08:00 AM - 08:10 AM		Introduction Steven Vernino, MD, PhD, F�鶹��ýӳ��
08:10 AM - 08:55 AM		Conventional Infections Causing Rapid Dementia Allen J. Aksamit, Jr., MD, F�鶹��ýӳ��
08:55 AM - 09:40 AM		CJD and Related Disorders Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
09:40 AM - 09:50 AM		Questions and Answers
09:50 AM - 10:10 AM		Break
10:10 AM - 10:55 AM		Autoimmune Encephalopathies Steven Vernino, MD, PhD, F�鶹��ýӳ��
10:55 AM - 11:40 AM		Rapidly Progressive Degenerative Dementia Kyle B. Womack, MD
11:40 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Steven Vernino, MD, PhD, F�鶹��ýӳ��	Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lundbeck. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WR Medical . Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Autonomic Neuroscience (Elsevier). The institution of Dr. Vernino has received research support from Takeda. The institution of Dr. Vernino has received research support from NIH/NHLBI. The institution of Dr. Vernino has received research support from Lundbeck. The institution of Dr. Vernino has received research support from Regeneron. Dr. Vernino has a non-compensated relationship as a Editor-in-Chief, Clinical Autonomic Research journal, with Springer Nature that is relevant to �鶹��ýӳ�� interests or activities.
Allen J. Aksamit, Jr., MD, F�鶹��ýӳ��	Dr. Aksamit has nothing to disclose.
Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Kyle B. Womack, MD	The institution of Dr. Womack has received research support from NIH. The institution of Dr. Womack has received research support from Janssen.